Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07376538 | Response-Based Local Therapy for Regionally Advanced Breast Cancer | recruiting | Phase 2 | 157 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07385365 | A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer | not yet recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2026 |
| clinicaltrials |
| NCT07396090 | Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors | not yet recruiting | N/A | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 9, 2026 | clinicaltrials |
| NCT07396142 | BaiXiaoAi AI Companion for Cancer Patient Follow-up | not yet recruiting | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 9, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03583619 | Randomized Trial of Accelerated Partial Breast Irradiation | completed | N/A | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07156045 | Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer | recruiting | Early Phase 1 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | recruiting | Phase 1 | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07298239 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC) | recruiting | Early Phase 1 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04821778 | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer | recruiting | Phase 3 | 2,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04821843 | Neoadjuvant Treatment Modalities in Esophageal Cancer | recruiting | Phase 3 | 2,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07286695 | Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 292 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07351266 | Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors | not yet recruiting | — | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07349160 | Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | recruiting | Early Phase 1 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 42 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT04320979 | Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients | active not recruiting | Phase 3 | 2,400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04528225 | A Prospective Study of Hypothyroidism After Radiotherapy for Breast Cancer | completed | — | 729 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06928922 | Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors. | recruiting | Early Phase 1 | 83 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT01413269 | Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery | completed | Phase 3 | 720 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07324798 | Adaptive Radiotherapy for Genitourinary Cancers(SMART-B01) | recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07317778 | Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer | not yet recruiting | Phase 2 | 249 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07307053 | Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) | not yet recruiting | Phase 1 / Phase 2 | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07279961 | A Multicenter Study on the Safety and Functionality Evaluation of Anastomotic Redo Surgery | completed | — | 143 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 12, 2025 | clinicaltrials |
| NCT05183074 | MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)(SMART-P01/02) | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05224934 | Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)(FUSION-01) | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05235100 | Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）(SPARE-02) | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05938374 | Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)(SPARE-03) | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05886439 | LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07232654 | Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07256002 | Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy | active not recruiting | — | 10,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06154538 | Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer | recruiting | Phase 2 | 170 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06904677 | Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer | recruiting | — | 400 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07239245 | Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo(ATTACH) | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07239271 | A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model | not yet recruiting | Phase 3 | 2,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT06848842 | Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186621 | Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC | recruiting | Phase 3 | 286 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186855 | Perioperative and Postoperative Circulating Tumor Cell Monitoring in Different Stage of NSCLC | completed | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07186868 | QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer | not yet recruiting | — | 25 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT06509009 | Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07164872 | Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer | not yet recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07166003 | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer(NeoIP-Lung) | recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07110090 | Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT) | recruiting | Phase 1 | 16 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07156019 | Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 4, 2025 | clinicaltrials |
| NCT07156058 | MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer | recruiting | N/A | 204 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06483698 | Real-world Clinical Outcomes of Patients With Early-stage Lung Cancer After the Surgery(EarlyLC-RW) | recruiting | — | 20,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07141771 | An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing | not yet recruiting | Phase 1 / Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07132242 | SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer | not yet recruiting | Phase 2 | 84 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 20, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials